Calamos Advisors LLC Invests $3.30 Million in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)

Calamos Advisors LLC purchased a new position in Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVNGet Rating) in the first quarter, HoldingsChannel reports. The firm purchased 27,800 shares of the company’s stock, valued at approximately $3,297,000.

A number of other institutional investors also recently made changes to their positions in BHVN. National Bank of Canada FI bought a new stake in shares of Biohaven Pharmaceutical in the 4th quarter worth approximately $28,000. Elkhorn Partners Limited Partnership bought a new stake in shares of Biohaven Pharmaceutical in the 4th quarter worth approximately $48,000. Montag A & Associates Inc. raised its holdings in shares of Biohaven Pharmaceutical by 16.7% in the 4th quarter. Montag A & Associates Inc. now owns 804 shares of the company’s stock worth $111,000 after purchasing an additional 115 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Biohaven Pharmaceutical in the 4th quarter worth approximately $220,000. Finally, Bailard Inc. bought a new stake in shares of Biohaven Pharmaceutical in the 4th quarter worth approximately $220,000. 88.03% of the stock is owned by institutional investors and hedge funds.

Biohaven Pharmaceutical Stock Down 0.2 %

Shares of BHVN opened at $145.95 on Monday. The company’s 50 day moving average price is $144.47 and its 200 day moving average price is $128.48. Biohaven Pharmaceutical Holding Company Ltd. has a 52 week low of $79.01 and a 52 week high of $151.51.

Biohaven Pharmaceutical (NYSE:BHVNGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($2.97) EPS for the quarter, missing analysts’ consensus estimates of ($2.52) by ($0.45). The company had revenue of $318.85 million for the quarter, compared to analysts’ expectations of $187.12 million. During the same quarter in the previous year, the firm earned ($4.21) earnings per share. As a group, equities research analysts anticipate that Biohaven Pharmaceutical Holding Company Ltd. will post -10.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on BHVN shares. Cantor Fitzgerald downgraded shares of Biohaven Pharmaceutical from an “overweight” rating to a “neutral” rating in a report on Wednesday, May 11th. Morgan Stanley cut their price target on shares of Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 6th. Piper Sandler cut their price target on shares of Biohaven Pharmaceutical from $156.00 to $149.00 and set a “na” rating on the stock in a report on Tuesday, May 24th. HC Wainwright lowered shares of Biohaven Pharmaceutical from a “buy” rating to a “neutral” rating in a report on Wednesday, May 11th. Finally, SVB Leerink lowered shares of Biohaven Pharmaceutical from an “outperform” rating to a “market perform” rating and set a $150.00 price target on the stock. in a report on Wednesday, May 11th. Five equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, Biohaven Pharmaceutical has an average rating of “Hold” and an average target price of $157.33.

Insiders Place Their Bets

In other Biohaven Pharmaceutical news, CAO George C. Clark sold 4,200 shares of the business’s stock in a transaction that occurred on Tuesday, May 10th. The shares were sold at an average price of $141.50, for a total value of $594,300.00. Following the completion of the sale, the chief accounting officer now directly owns 4,065 shares of the company’s stock, valued at $575,197.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 12.40% of the company’s stock.

Biohaven Pharmaceutical Company Profile

(Get Rating)

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.

Featured Stories

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVNGet Rating).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.